Pascolizumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized(frommouse) |
| Target | IL-4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
  (what is this?)(verify) | |
Pascolizumabis ahumanized monoclonal antibodyfor the treatment ofasthma.[1]A Phase IIclinical trialin patients with symptomaticglucocorticoidnaive asthma was conducted in 2001/2002.[2]Development was discontinued as it showed little benefit.[3]
References
[edit]- ^Hart TK, Blackburn MN, Brigham-Burke M, Dede K, Al-Mahdi N, Zia-Amirhosseini P, Cook RM (October 2002)."Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma".Clinical and Experimental Immunology.130(1): 93–100.doi:10.1046/j.1365-2249.2002.01973.x.PMC1906490.PMID12296858.
- ^Clinical trial numberNCT00024544for "Pilot Study in Patients With Symptomatic Steroid-Naive Asthma" atClinicalTrials.gov
- ^Bice JB, Leechawengwongs E, Montanaro A (2014). "Biologic targeted therapy in allergic asthma".Annals of Allergy, Asthma & Immunology.112(2): 108 - 115.doi:10.1016/j.anai.2013.12.013.
 | Thismonoclonal antibody–related article is astub.You can help Wikipedia byexpanding it. |
 | Thisantineoplasticorimmunomodulatorydrugarticle is astub.You can help Wikipedia byexpanding it. |